抑制7α,26-二基胆固醇生物合成促进中脑多巴胺基神经元发育
James Hennegan1,2, Aled H Bryant1, Lauren Griffiths1,3,4
1Regenerative Neurobiology Laboratory, Swansea University Medical School, Institute of Life Science 1, Singleton Park, Swansea SA2 8PP, UK.
iScience
|December 29, 2023
概括
升高的胆固醇代谢物7α,26-diHC损害了帕金森病 (PD) 中的多巴胺神经元发育. 作为CYP7B1抑制剂的沃里康纳可以保护这些神经元,这表明它对PD有潜在的治疗应用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
背景情况:
- 失调的胆固醇代谢与神经退行性疾病有关.
- 之前在帕金森病 (PD) 脑脊液中观察到7α,26-二氧胆固醇 (7α,26-diHC) 的升高水平.
研究的目的:
- 研究7α,26-diHC在中脑多巴胺 (mDA) 神经元的发育和存活中的作用.
- 在PD的背景下探索CYP7B1抑制的潜在神经保护作用.
主要方法:
- 使用人类胚胎干细胞 (hESC) 衍生和老鼠祖先培养物.
- 评估了7α,26-diHC和voriconazole (一种CYP7B1抑制剂) 对mDA神经元数量和亡的影响.
- 通过检查眼运动神经元群体来评估这些效应的特异性.
主要成果:
- 发现7α,26-diHC在hESC和小鼠培养物中诱导了亡并减少了mDA神经元数量.
- 沃里康纳治疗增加了mDA神经元数量,并预防了7α,26-diHC诱导的神经退行.
- 无论是7α,26-diHC还是沃里科纳都没有影响Islet1+眼运动神经元数量,这表明特异性.
- 升高的24(S),25-环氧胆固醇可能部分调解沃里康纳对mDA神经元的有益作用.
结论:
- 7α,26-diHC在mDA神经元的发育和存活中起着不利的作用.
- 伏利康纳所示的CYP7B1抑制表明了mDA神经元的神经保护潜力.
- 醇CYP7B1抑制剂代表了开发新型帕金森病疗法的有前途途途.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
567
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
567
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
985
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
985
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
Parkinson's Disease: Treatment
273
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
273


